{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:45:38Z","timestamp":1793375138960,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.semnephrol.2010.09.006","type":"journal-article","created":{"date-parts":[[2010,12,10]],"date-time":"2010-12-10T09:15:03Z","timestamp":1291972503000},"page":"582-590","source":"Crossref","is-referenced-by-count":39,"title":["Biology of Anti-Angiogenic Therapy\u2013Induced Thrombotic Microangiopathy"],"prefix":"10.1016","volume":"30","author":[{"given":"Vera","family":"Eremina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Quaggin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2010.09.006_bib1","doi-asserted-by":"crossref","first-page":"20017","DOI":"10.1016\/S0021-9258(19)47212-8","article-title":"Human vascular permeability factor","volume":"264","author":"Connolly","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib2","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","article-title":"Vascular endothelial growth factor is a secreted angiogenic mitogen","volume":"246","author":"Leung","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib3","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib4","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nrc909","article-title":"VEGF and the quest for tumour angiogenesis factors","volume":"2","author":"Ferrara","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib5","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/IAE.0b013e318176de48","article-title":"Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema","volume":"28","author":"Kook","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib6","doi-asserted-by":"crossref","first-page":"129873","DOI":"10.1155\/2008\/129873","article-title":"Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention","volume":"2008","author":"Yoo","year":"2008","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib7","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/S0140-6736(07)61625-0","article-title":"New treatments for age-related macular degeneration","volume":"370","author":"Avery","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib8","doi-asserted-by":"crossref","first-page":"11947","DOI":"10.1016\/S0021-9258(18)99049-6","article-title":"The human gene for vascular endothelial growth factor","volume":"266","author":"Tischer","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib9","first-page":"4123","article-title":"VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma","volume":"62","author":"Bates","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib10","doi-asserted-by":"crossref","first-page":"7822","DOI":"10.1158\/0008-5472.CAN-04-0934","article-title":"VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression","volume":"64","author":"Woolard","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib11","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/nrc2505","article-title":"VEGF-A splicing: the key to anti-angiogenic therapeutics?","volume":"8","author":"Harper","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib12","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2010030295","article-title":"Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling","author":"Sison","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/376066a0","article-title":"Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium","volume":"376","author":"Fong","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib14","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1073\/pnas.90.16.7533","article-title":"Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium","volume":"90","author":"Quinn","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib15","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/nature00821","article-title":"VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism","volume":"417","author":"Gerber","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib16","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V97.3.785","article-title":"Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans","volume":"97","author":"Sawano","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib17","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/S0959-8049(96)00387-5","article-title":"Vascular endothelial growth factor","volume":"32A","author":"Ferrara","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib18","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/376062a0","article-title":"Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice","volume":"376","author":"Shalaby","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib19","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1161\/ATVBAHA.107.158022","article-title":"The molecular basis of VEGFR-1 signal transduction pathways in primary human monocytes","volume":"28","author":"Tchaikovski","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib20","doi-asserted-by":"crossref","first-page":"14016","DOI":"10.1073\/pnas.0503544102","article-title":"VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice","volume":"102","author":"Niida","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib21","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1172\/JCI17423","article-title":"Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases","volume":"111","author":"Eremina","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib22","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1681\/ASN.2005080810","article-title":"VEGF-A signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival","volume":"17","author":"Eremina","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib23","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/019262339902700115","article-title":"Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody","volume":"27","author":"Ryan","year":"1999","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib26","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1242\/dev.126.6.1149","article-title":"VEGF is required for growth and survival in neonatal mice","volume":"126","author":"Gerber","year":"1999","journal-title":"Development"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib27","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1172\/JCI6740","article-title":"VEGF(165) mediates glomerular endothelial repair","volume":"104","author":"Ostendorf","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib28","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib29","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib30","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(07)70285-1","article-title":"Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study","volume":"8","author":"Rixe","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib31","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/ncpneph0476","article-title":"Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma","volume":"3","author":"Roncone","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(07)70037-2","article-title":"Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma","volume":"8","author":"Frangie","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib33","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/ki.2008.256","article-title":"Glomerular disease related to anti-VEGF therapy","volume":"74","author":"Stokes","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib34","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/ndt\/gfl565","article-title":"Thrombotic microangiopathy and anti-VEGF agents","volume":"22","author":"Izzedine","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib35","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/ndt\/gfn657","article-title":"Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib","volume":"24","author":"Bollee","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib36","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1681\/ASN.2007020255","article-title":"The glomerular injury of preeclampsia","volume":"18","author":"Stillman","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib37","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1172\/JCI17189","article-title":"Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia","volume":"111","author":"Maynard","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib38","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating angiogenic factors and the risk of preeclampsia","volume":"350","author":"Levine","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib39","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1056\/NEJMoa055352","article-title":"Soluble endoglin and other circulating antiangiogenic factors in preeclampsia","volume":"355","author":"Levine","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib40","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1200\/JCO.2008.19.0108","article-title":"Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma","volume":"27","author":"Feldman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib41","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/jnci\/djm311","article-title":"A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib","volume":"100","author":"Patel","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib42","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib43","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1093\/ndt\/gfm199","article-title":"Interstitial nephritis in a patient taking sorafenib","volume":"22","author":"Izzedine","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib44","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1053\/j.ajkd.2006.11.024","article-title":"Nephrotic syndrome after bevacizumab: case report and literature review","volume":"49","author":"George","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib45","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/sj.ki.5001891","article-title":"Chronic lymphocytic leukemia and cryoglobulinemic glomerulonephritis","volume":"71","author":"Nasr","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib46","doi-asserted-by":"crossref","first-page":"14448","DOI":"10.1073\/pnas.0703577104","article-title":"Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions","volume":"104","author":"Advani","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib47","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1074\/jbc.C300012200","article-title":"Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria","volume":"278","author":"Sugimoto","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib48","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.cell.2007.06.054","article-title":"Autocrine VEGF signaling is required for vascular homeostasis","volume":"130","author":"Lee","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib49","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1371\/journal.pmed.0040186","article-title":"Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1\/FLT1","volume":"4","author":"Lee","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib50","doi-asserted-by":"crossref","first-page":"F422","DOI":"10.1152\/ajprenal.00448.2005","article-title":"Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP","volume":"291","author":"Guan","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib51","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2353\/ajpath.2006.050834","article-title":"Vascular endothelial growth factor localization in the adult","volume":"168","author":"Maharaj","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib52","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10157-009-0167-5","article-title":"Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma","volume":"13","author":"Jonkers","year":"2009","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib53","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev.pathmechdis.3.121806.154311","article-title":"Pathogenesis of thrombotic microangiopathies","volume":"3","author":"Zheng","year":"2008","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib54","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic-uremic syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2010.09.006_bib55","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1200\/JCO.2008.16.1612","article-title":"Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100","volume":"26","author":"Schneider","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929510001385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929510001385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T02:00:16Z","timestamp":1636941616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929510001385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0270929510001385"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2010.09.006","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}